Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 621

1.

Inhibiting MEK in MAPK pathway activated myeloma.

Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G.

Leukemia. 2015 Jul 31. doi: 10.1038/leu.2015.208. [Epub ahead of print] No abstract available.

PMID:
26228812
2.

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A, Barlogie B, Shaughnessy JD Jr, Epstein J, Sundan A.

Genes Chromosomes Cancer. 2015 Jul 29. doi: 10.1002/gcc.22280. [Epub ahead of print]

PMID:
26220195
3.

Using a latent class model to refine risk stratification in multiple myeloma.

Qu P, Barlogie B, Crowley J.

Stat Med. 2015 Sep 20;34(21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17.

PMID:
26084662
4.

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B.

Haematologica. 2015 May 28. pii: haematol.2015.124651. [Epub ahead of print]

5.

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B.

Blood. 2015 Jun 11;125(24):3756-9. doi: 10.1182/blood-2015-03-632075. Epub 2015 May 5.

PMID:
25943786
6.

Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat.

Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B.

BMC Bioinformatics. 2015 Feb 25;16:63. doi: 10.1186/s12859-015-0478-3.

7.

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B.

Clin Case Rep. 2015 Mar;3(3):183-92. doi: 10.1002/ccr3.180. Epub 2015 Feb 13.

8.

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Mar 10. doi: 10.1038/leu.2015.65. [Epub ahead of print]

PMID:
25753926
9.

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B.

Leukemia. 2015 May;29(5):1195-201. doi: 10.1038/leu.2015.15. Epub 2012 Feb 2.

10.

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E.

J Clin Oncol. 2015 Feb 20;33(6):657-64. doi: 10.1200/JCO.2014.57.9961. Epub 2015 Jan 20.

PMID:
25605835
11.

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.

Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, Usmani SZ.

Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93. No abstract available.

12.

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.

Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F.

J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059.

13.

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.

14.

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.

Usmani SZ, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, Waheed S, Van Rhee F, Crowley J, Barlogie B.

Leukemia. 2014 Dec;28(12):2413-5. doi: 10.1038/leu.2014.248. Epub 2014 Aug 25. No abstract available.

PMID:
25151956
15.

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.

Bam R, Venkateshaiah SU, Khan S, Ling W, Randal SS, Li X, Zhang Q, van Rhee F, Barlogie B, Epstein J, Yaccoby S.

Blood Cancer J. 2014 Aug 1;4:e234. doi: 10.1038/bcj.2014.54.

16.

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma.

Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A, Crowley J, Barlogie B.

Leukemia. 2014 Dec;28(12):2410-3. doi: 10.1038/leu.2014.232. Epub 2014 Jul 31. No abstract available.

17.

CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S.

Blood. 2014 Sep 25;124(13):2051-60. doi: 10.1182/blood-2014-02-555813. Epub 2014 Jul 24.

PMID:
25061178
18.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP.

Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15. Review.

19.

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis.

Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J, Heuck C.

Oncotarget. 2014 Jun 30;5(12):4118-28.

20.

Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance.

Yang JD, Girotra M, Restrepo A, Waheed S, Barlogie B, Duarte-Rojo A.

Ann Hepatol. 2014 Jul-Aug;13(4):461-5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk